The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men

Objective: Inadequate adherence to highly active antiretroviral therapy (HAART) may lead to poor health outcomes and the development of HIV strains that are resistant to HAART. The authors developed a model to evaluate the cost-effectiveness of counseling interventions to improve adherence to HAART among men who have sex with men (MSM). Methods. The authors developed a dynamic compartmental model that incorporates HIV treatment, adherence to treatment, and infection transmission and progression. All data estimates were obtained from secondary sources. The authors evaluated a counseling intervention given prior to initiation of HAART and before all changes in drug regimens, combined with phone-in support while on HAART. They considered a moderate-prevalence and a high-prevalence population of MSM. Results. If the impact of HIV transmission is ignored, the counseling intervention has a cost-effectiveness ratio of $25,500 per quality-adjusted life year (QALY) gained. When HIV transmission is included, the cost-effectiveness ratio is much lower: $7400 and $8700 per QALY gained in the moderate- and high-prevalence populations, respectively. When the intervention is twice as costly per counseling session and half as effective as estimated in the base case (in terms of the number of individuals who become highly adherent, and who remain highly adherent), then the intervention costs $17,100 and $19,600 per QALY gained in the 2 populations, respectively. Conclusions. Counseling to improve adherence to HAART increased length of life, modestly reduced HIV transmission, and cost substantially less than $50,000 per QALY gained over a wide range of assumptions but did not reduce the proportion of drug-resistant strains. Such counseling provides only modest benefit as a tool for HIV prevention but can provide significant benefit for individual patients at an affordable cost.

[1]  J. Leonard,et al.  Decrease of HIV‐1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine , 1998, AIDS.

[2]  Milton C Weinstein,et al.  Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.

[3]  B. Roca,et al.  Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. , 1999, The Journal of infection.

[4]  Blair T. Johnson,et al.  Efficacy of Antiretroviral Therapy Adherence Interventions: A Research Synthesis of Trials, 1996 to 2004 , 2006, Journal of acquired immune deficiency syndromes.

[5]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[6]  E. Vittinghoff,et al.  Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. , 1997, American journal of epidemiology.

[7]  J. Schapiro,et al.  Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV‐Infected Patients in the VIRADAPT Study , 2000, Journal of acquired immune deficiency syndromes.

[8]  L. Rodrigues,et al.  Heterosexual transmission of HIV. , 1992, BMJ.

[9]  M. Otto,et al.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. , 2001, Behaviour research and therapy.

[10]  Julio S. G. Montaner,et al.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.

[11]  G. Peytavin,et al.  Relationship between Levels of Indinavir in Hair and Virologic Response to Highly Active Antiretroviral Therapy , 2002, Annals of Internal Medicine.

[12]  T. Coates,et al.  Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco Men's Health Study. , 1990, American journal of public health.

[13]  D. Cooper,et al.  Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV‐1‐infected individuals , 1998, AIDS.

[14]  A. Mocroft,et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.

[15]  G. Godin,et al.  Efficacy of interventions in improving adherence to antiretroviral therapy , 2005, International journal of STD & AIDS.

[16]  R. Royce,et al.  Sexual transmission of HIV. , 1997, The New England journal of medicine.

[17]  H. Günthard,et al.  Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial , 2004, Antiviral therapy.

[18]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[19]  V. Robison,et al.  Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.

[20]  A. Egberts,et al.  Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[21]  F. Hecht,et al.  Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 , 2000, Journal of Clinical Microbiology.

[22]  D. Vlahov,et al.  A PROSPECTIVE STUDY OF ADHERENCE AND VIRAL LOAD IN A LARGE MULTI-CENTER COHORT OF HIV-INFECTED WOMEN , 2002, AIDS.

[23]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[24]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[25]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[26]  I. de Vincenzi,et al.  Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[27]  Joel Tsevat,et al.  The Will To Live among HIV-Infected Patients , 1999, Annals of Internal Medicine.

[28]  A. Guerrero,et al.  Risk factors for ritonavir intolerance and outcome after change to indinavir. , 1998, AIDS.

[29]  F. Maggiolo,et al.  Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients , 2002, HIV clinical trials.

[30]  Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response , 2000 .

[31]  A. Mocroft,et al.  Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.

[32]  L. Pollack,et al.  Bringing HIV/STI testing programmes to high-risk men. , 2005, International journal of STD & AIDS.

[33]  J. Parsons,et al.  Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. , 2005, AIDS patient care and STDs.

[34]  T. Heeren,et al.  Unsafe sex in men who have sex with both men and women. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[35]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[36]  Douglas K Owens,et al.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.

[37]  R. Hogg,et al.  Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[38]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[39]  W. Heneine,et al.  Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities , 2002, International journal of STD & AIDS.

[40]  Richard D Moore,et al.  Hepatitis C and progression of HIV disease. , 2002, JAMA.

[41]  S. Weller,et al.  The effectiveness of condoms in reducing heterosexual transmission of HIV. , 1999, Family planning perspectives.

[42]  M. Egger,et al.  Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. , 2000, Archives of internal medicine.

[43]  P. Domingo,et al.  Switching HIV-1 protease inhibitor therapy: which? When? And why? , 1999, Archives of internal medicine.

[44]  D. Richman,et al.  Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.

[45]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[46]  Donald A. Redelmeier,et al.  Economic methods for measuring the quality of life associated with HIV infection , 1999, Quality of Life Research.

[47]  J. Alcamí,et al.  Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. , 1999, Journal of acquired immune deficiency syndromes.

[48]  R Rode,et al.  Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.

[49]  C. Quereda,et al.  Effectiveness and Pitfalls of Initial Highly Active Antiretroviral Therapy in HIV-Infected Patients in Routine Clinical Practice , 1999, Antiviral therapy.

[50]  R. Pollard Can HIV infection be treated successfully with a once-daily regimen? , 2002, The AIDS reader.

[51]  V. Diehl,et al.  Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study. , 1999, European journal of medical research.

[52]  R. Chaisson,et al.  Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.

[53]  R. Hogg,et al.  The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study , 1998, AIDS.

[54]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[55]  Margaret L. Brandeau,et al.  The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study , 1998, Simul..

[56]  M. Opravil,et al.  The SPICE Study: 48‐Week Activity of Combinations of Saquinavir Soft Gelatin and Nelfinavir With and Without Nucleoside Analogues , 2000, Journal of acquired immune deficiency syndromes.

[57]  D. Katzenstein,et al.  Rapid Communication: Efavirenz‐ and Adefovir Dipivoxil‐Based Salvage Therapy in Highly Treatment‐Experienced Patients: Clinical and Genotypic Predictors of Virologic Response , 2000, Journal of acquired immune deficiency syndromes.

[58]  Robert Shafer,et al.  HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.

[59]  D A Revicki,et al.  Change in clinical status, health status, and health utility outcomes in HIV-infected patients. , 1995, Medical care.

[60]  Are nelfinavir-containing regimens effective as second-line triple therapy? , 2000, AIDS.

[61]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2001, Nature Medicine.

[62]  Douglas K Owens,et al.  Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis , 1993 .

[63]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[64]  B. Yip,et al.  Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.

[65]  M L Brandeau,et al.  HIV transmission and the cost-effectiveness of methadone maintenance. , 2000, American journal of public health.

[66]  J. Casado,et al.  Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study , 2002, AIDS.

[67]  R. D. Webster,et al.  HIV testing among men who have sex with men: how often should one test? , 2005, Journal of public health management and practice : JPHMP.

[68]  J. Bartlett,et al.  Highly active antiretroviral therapy and sexual risk behavior: A metaanalytic review , 2004 .

[69]  A. Hurley,et al.  Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals , 2002, AIDS.

[70]  D. Haas,et al.  Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  B. Turner Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. , 2002, The Journal of infectious diseases.

[72]  B. Boyle Editorial comment: once-daily antiretroviral therapy. , 2002, The AIDS reader.

[73]  R. Hays,et al.  A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.

[74]  Joseph Quinn,et al.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults , 2006, AIDS.

[75]  S. Vermund,et al.  Adherence to HAART among HIV-infected persons in rural Louisiana. , 2004, AIDS patient care and STDs.

[76]  T. Coates,et al.  Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV‐negative, HIV‐positive and untested , 1997, AIDS.

[77]  S. Ra,et al.  High-risk sexual behavior and condom use among gay and bisexual men. , 1993 .

[78]  A. Wu,et al.  Interventions to Improve Adherence to Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[79]  A. Carballo-Diéguez,et al.  Couple-focused support to improve HIV medication adherence: a randomized controlled trial , 2005, AIDS.

[80]  B. Roca,et al.  A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients , 2000, AIDS.

[81]  U. C. Bureau Statistical Abstract of the United States , 2004 .

[82]  J. Gallant,et al.  Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. , 1999, AIDS.

[83]  A. Sönnerborg,et al.  Persistence of earlier HIV‐1 drug resistance mutations at new treatment failure , 2002, Journal of medical virology.

[84]  M. Saag,et al.  Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.

[85]  J. Goedert,et al.  Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. , 2000, The Journal of infectious diseases.

[86]  T. Coates,et al.  High HIV risk-taking among young gay men. , 1990, AIDS.

[87]  M. Lederman,et al.  Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. , 1999, Archives of internal medicine.

[88]  M. Moroni,et al.  Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral‐experienced patients in advanced stages of HIV‐1 infection , 1998, AIDS.

[89]  Edward H. Kaplan Asymptotic worst-case mixing in simple demographic models of HIV/AIDS. , 1992, Mathematical biosciences.

[90]  G. Marks,et al.  Prevalence of high-risk sex among HIV-positive gay and bisexual men: a longitudinal analysis. , 1996, American journal of preventive medicine.

[91]  F. Parazzini,et al.  Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study , 2000, Journal of acquired immune deficiency syndromes.

[92]  T. Coates,et al.  Unprotected sex and HIV risk taking among young gay men within boyfriend relationships. , 1997, AIDS education and prevention : official publication of the International Society for AIDS Education.

[93]  C. Boucher,et al.  Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). , 1999, AIDS.

[94]  H. Gershengorn,et al.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.

[95]  J. Ward,et al.  Statistical analysis of the stages of HIV infection using a Markov model. , 1989, Statistics in medicine.

[96]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[97]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[98]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[99]  D K Owens,et al.  Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. , 1992, Archives of internal medicine.

[100]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[101]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[102]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[103]  P. Barton,et al.  Antidepressant Treatment Improves Adherence to Antiretroviral Therapy Among Depressed HIV-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[104]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[105]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[106]  Richard D Moore,et al.  Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? , 2002, AIDS patient care and STDs.

[107]  M C Weinstein,et al.  Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. , 1996, Medical care.

[108]  I. de Vincenzi,et al.  A Longitudinal Study of Human Immunodeficiency Virus Transmission by Heterosexual Partners , 1994 .

[109]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[110]  P. Bellman Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed , 1998, AIDS.

[111]  B. Ledergerber,et al.  Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. , 1999, AIDS research and human retroviruses.

[112]  K. Kabeya,et al.  Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine. , 1999, AIDS.

[113]  P. Duong,et al.  Virologic response associated with a change in protease inhibitor therapy. , 2000, Archives of internal medicine.

[114]  Prabhat Jha,et al.  Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. , 2002, Bulletin of the World Health Organization.

[115]  Elaine R Reynolds,et al.  Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. , 2004, AIDS patient care and STDs.

[116]  C. Rietmeijer,et al.  HIV serostatus disclosure among gay and bisexual men in four American cities: general patterns and relation to sexual practices. , 1998, AIDS care.

[117]  E. Kohli,et al.  Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  C Inch,et al.  Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. , 2006, The Cochrane database of systematic reviews.

[119]  C. Quereda,et al.  Predictors of long‐term response to protease inhibitor therapy in a cohort of HIV‐infected patients , 1998, AIDS.

[120]  R. Hogg,et al.  HIV infection and risk behaviours among young gay and bisexual men in Vancouver. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[121]  C. Castillo-Chavez Mathematical and Statistical Approaches to Aids Epidemiology , 1989 .

[122]  R. Paredes,et al.  High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. , 1999, Journal of acquired immune deficiency syndromes.

[123]  N. Jewell,et al.  Female-to-male transmission of human immunodeficiency virus. , 1992, JAMA.

[124]  W. Mcfarland,et al.  Very Young Gay and Bisexual Men Are at Risk for HIV Infection: The San Francisco Bay Area Young Men's Survey II , 2000, Journal of acquired immune deficiency syndromes.

[125]  Mark Dybul,et al.  Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.

[126]  B. Leynaert,et al.  Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. , 1998, American journal of epidemiology.

[127]  R. Rohrsheim,et al.  Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. , 2005, International journal of STD & AIDS.

[128]  A. Phillips,et al.  Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.

[129]  Melissa R. Pfeiffer,et al.  Estimation of HIV Prevalence, Risk Factors, and Testing Frequency among Sexually Active Men Who Have Sex with Men, Aged 18–64 Years—New York City, 2002 , 2007, Journal of Urban Health.

[130]  L. Kalish,et al.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.

[131]  D. Watts,et al.  Small Worlds: The Dynamics of Networks between Order and Randomness , 2001 .

[132]  P. Vernazza,et al.  Probability of heterosexual transmission of HIV. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[133]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[134]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[135]  B. Turner,et al.  Antiretroviral adherence interventions: a review of current literature and ongoing studies. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[136]  W Winkelstein,et al.  Male-to-female transmission of human immunodeficiency virus. , 1987, JAMA.

[137]  P. Jatlow,et al.  Modified directly observed therapy (MDOT) for injection drug users with HIV disease. , 2002, The American journal on addictions.

[138]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[139]  P. Bonfanti,et al.  Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients. , 1998, AIDS.

[140]  C. Hoff,et al.  HIV risk among Latino gay men in the Southwestern United States. , 1996, AIDS education and prevention : official publication of the International Society for AIDS Education.

[141]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[142]  J. Catania,et al.  High-risk sexual behavior and condom use among gay and bisexual African-American men. , 1992, American journal of public health.

[143]  J. Rockstroh,et al.  Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients , 1997, AIDS.

[144]  O. Kirk,et al.  Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. , 1999, AIDS.

[145]  T. Coates,et al.  Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. , 1999, AIDS.

[146]  L. Eldred,et al.  The cost of HIV medication adherence support interventions: Results of a cross-site evaluation , 2005, AIDS care.

[147]  S. Kippax,et al.  In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk reduction rather than unbridled sex , 2002, AIDS care.

[148]  R. Janssen,et al.  HIV incidence among young men who have sex with men--seven U.S. cities, 1994-2000. , 2001, MMWR. Morbidity and mortality weekly report.

[149]  D. Bangsberg,et al.  Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[150]  David Madigan,et al.  Implementation Brief: A Two-way Messaging System to Enhance Antiretroviral Adherence , 2003, J. Am. Medical Informatics Assoc..

[151]  J. Elvira,et al.  Effect of Patient Adherence to Antiretroviral Therapy on CD4+ Cell Count, HIV-1 RNA, and Serum Concentrations of Tumor Necrosis Factor and its Soluble Receptors , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[152]  W. Bilker,et al.  Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.

[153]  J. Dilley,et al.  Psychosocial correlates of unprotected anal sex in a cohort of gay men attending an HIV-negative support group. , 1998, AIDS education and prevention : official publication of the International Society for AIDS Education.

[154]  R. Sperling Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. , 1997 .

[155]  I. de Vincenzi A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. , 1994, The New England journal of medicine.

[156]  David R. Holtgrave,et al.  Estimating the cost of unmet HIV-prevention needs in the United States. , 2002, American journal of preventive medicine.

[157]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2003, Nature Medicine.

[158]  J. Elford,et al.  Sexual risk behaviour among gay men in a relationship. , 1999, AIDS.

[159]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[160]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[161]  V. Stone,et al.  Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[162]  Edward H. Kaplan,et al.  Nonrandom mixing models of HIV transmission , 1989 .

[163]  M. Fletcher,et al.  Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. , 1999, Journal of acquired immune deficiency syndromes.